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The central nervous system (CNS) consists of a series of complex structures which comprise 
cellular elements with basic communication functions and elaboration of information as part 
of their role in the process of biological adaptation and maintenance of homeostasis [Hickey 
WF, 2001]. 
1.1 Mayor components of the CNS  
The major components of the CNS; neurons and neurites, microglias, astrocytes, ependymal 
cells and oligodendrocytes, establish all an important interrelationship, vital to the brain 
maintenance homeostasis. Ependymal cells lay around layers of astrocytes, which in turn 
envelop neurons, neurites and vascular elements. In addition, the normal CNS parenchyma 
contains blood vessels and resident macrophages. Glial cells, as they possess no 
conventional synaptic contacts, differ from neurons mainly establishing a rich 
interrelationship with other CNS components. The neuroglia, brain interstitial element, is 
recognized as including three groups of glial cells: 1) macroglias, such as astrocytes and 
oligodendrocytes,2) microglia and 3) ependymal cells. 
Regarding glial function, the astrocytes are involved in glutamate uptake, repair and 
transport, and are part of the blood brain barrier (BBB). Studies conducted by Reese and 
Karnowosky [1967] indicate that the astrocyte end-feet provide little resistance to molecule 
movement, and that the blockage of their passage into the brain occurs at the endothelial-
cell-lining blood vessels. In this case, endothelial cells forming for brain vascular 
endothelium, play an important role in the communication between the CNS and the 
periphery, this latter understood as intravascular space. 
Oligodendrocytes are the myelin producing cells within the CNS and are potentially highly 
vulnerable to immune mediated damage, since they share together with the myelin sheath 
many molecules with affinities to elicit specific T and B cell responses, which lead to their 
destruction. Oligodendrocytes do not express class I or II MHC molecules, but a wide 
profile of cytokine receptors, both pro-inflammatory and regulatory which have been found 
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on this cell-type, suggesting their innate and adaptative ability to participate in immune 
response. 
Microglial cells, the most interesting and enigmatic CNS type cells, play a role in 
phagocytosis and inflammatory response in the CNS. Under normal conditions these cells 
seem to be in a resting state, becoming a very active macrophage during the disease, and 
constituting the major effector cell in immune-mediated damage in the CNS. An explosive 
activity in the field of microglia cell-research conducted in the past 15 to 20 years has led to 
the identification of microglia as a highly efficient accessory and effector cell of the immune 
system. Microglia expresses class II MHC antigen upon activation Perry & Gordon, 1997 in 
the absence of a T cell response, which suggests that major histocompatibility complex 
(MHC) antigen expression may represent a marker of activation and/or a state of 
immunological competence. Microglia are also major producers of a large number of 
proinflammatory cytokines with well-known effects on T cells Perry & Gordon, 1997. All 
the previous information supports a wide glial involvement in brain internal homeostasis 
maintenance that plays a major role in the regulatory function of barrier systems. 
1.2 Brain neurovascular unit  
The blood-brain barrier (BBB) system, located between the intravascular space and the brain 
tissue, constitutes a phenomenon of selective permeability and reduced exchange of 
products between the blood and the nervous system. It is a characteristic of brain capillaries 
and is regulated by the cells that form the neurovascular unit (NVU) Becher et al, 2006; 
Nathanson & Chun, 1990; Seyfert & Faultish, 2003 and the dynamics of cerebrospinal fluid 
(CSF) flow Becher et al, 2006; Seyfert & Faultish, 2003. NVU refers to the dynamic 
exchange among the cellular elements forming these barriers in the brain; there is a regional 
specialized interface between the neural tissue and the blood Neutwelt et al, 2008. 
The NVU is formed by: 1) The CSF-blood barrier, site of immunological communication 
between the CSF and intravascular space, which favours antigenic recognition and 
lymphocyte activation at this level Bigio, 1995; Nathanson & Chun, 1990a; Redzic et al, 
2005; 2) The meningeal barrier, that is, the aracnoid membrane, bordering the duramater, 
where the CSF drains to the dural venous sinuses, the olfactory nerve and the carotid 
sheathsNag S. 2003; 3) the BBB, constituted by the brain vascular endothelium, regulates 
the entrance of molecules and supply of nutrients to the brain, as well as preserving the 
ionic homeostasis in the brain environment Petty & Lo, 2002; 4) the blood-nerve barrier, 
which surrounds the axon tangles and includes the endothelial membrane of the endoneural 
capillary and the perinerium Hemmer, 2004; 5) the blood–retinal barrier, formed by the 
retinal endothelial capillary and the retinal tissue, like BBB; 6) the blood-labyrinth barrier, 
which has as anatomical reference the endolymph-blood and endolymph-perilymph 
barriers.These capillaries are lined with endothelial cells that are joined by tight junctions 
and physiologically form the blood–labyrinth barrier that is essential for sensitive auditory 
function; and 7) the blood-spinal cord barrier - with a greater permeability than the BBB - 
which communicates with the periphery through the nerve roots plexus Haukins  Davis , 
2005. 
For centuries, the BBB, the lack of conventional lymphatic drainage and low response to 
aloantigens inoculated in the CNS, were arguments to consider this compartment as a 
www.intechopen.com
 
Glial and Axonal Pathology in Multiple Sclerosis 
 
105 
privileged site. Nevertheless, today it is well known, that there is no such privilege, but 
rather the main differences of the immune response in the brain, regarding the periphery, 
are in the kinetics and the degree of regulation of the different stages of the immune 
response at this level, which will take place under the functional control of the immune 
response and influence of cellular mediators acting in a regulated quantitative and 
temporally balanced sequenceFisher  Gage, 1993.  
In normal conditions, neurons are unable to interact with T-cells, via MHC expression 
antigens, however, neurons possess unique antigenic proteins, which are normally 
sequestered by the BBB from the circulating immune system, making the CNS vulnerable 
to immune-mediated damage. On the other hand, there is increasing evidence on the 
ability of astrocytes to act as accessory cells of the immune system, as a facultative 
phagocyte able to interact with lymphocytes, since astrocytes express class II MHC 
antigens, essential molecules for antigen presentation to T helper cells. Astrocytes are also 
able to synthesize cytokines like interleukin 1, interferon  and tumor necrosis factor, 
among others. During inflammation, the mechanism of selective transport displayed by 
endothelial cells (EC) is disrupted and endothelial tight junctions display altered 
permeability with subsequent edema within and around neighboring astrocytes. Evidence 
of the immunological role of microglia in demyelinating diseases like Multiple Sclerosis, 
as well as evidences of their putative role as a major effector-cell of immune mediated cell 
damage at this level has been well established. 
1.3 Astrocytes as dynamic regulators of neuronal functional activity 
One of the main functions of astrocytes is the uptake of neurotransmitters released from 
nerve terminals. But astrocytes can also release neuroactive agents, including transmitters, 
eicosanoids, steroids, neuropeptides and growth factors [Anderson  Swanson, 2000]. The 
regulation and mechanism (or mechanisms) of astrocyte-mediated release of neuroactive 
compounds are for most agents poorly defined. Release of glutamate appears to be the 
primary mechanism by which astrocytes modulate synaptic transmission [Kang, 1998].  
In addition, astrocytes might serve neurons not so much as servants but as parents – both 
literally, as a developmental source of new neurons, and figuratively, as the regulators and 
judges of neuronal behaviour and activities. Simply stated, astrocytes command neurons 
what to do, besides keeping their environment clean. Interactions among astrocytes, 
neurons and endothelial cells define the gliovascular unit.  
BBB is a diffusion barrier that regulates the exchange of molecules between the two tissues. 
The primary seal of the blood–brain barrier is formed by endothelial tight junctions. 
Astrocytes enwrap the vasculature with a large number of endfeet covering the vessel wall, 
although their role in BBB is poorly defined, they do not have a barrier function in the 
mammalian brain [del Zoppo  Hallenbeck, 2000]. Several factors released by astrocytes 
might be important for the induction and maintenance of the blood–brain barrier, as 
manifested by the appearance of endothelial tight junctions in cells ensheathed by astrocytic 
endfeet. Several investigators have studied this issue and have identified agents released by 
astrocytes, including transforming growth factor-a (TGFa) and glial-derived neurotrophic 
factor (GDNF), that support the formation of tight junctions in cultured endothelial cells 
[Abbott, 2002].  
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In general, the interactions between the barriers conforming the neurovascular unit, 
constitute the base of pathological events involved in neurological diseases, with 
inflammatory, neurodegenerative or autoimmune components as in MS, neuromyelitis 
optica (NMO), posterior uveitis, CNS vasculitis, cerebral ischemia, Alzheimer´s disease, 
among others Brown, 2001 and at the same time they derive from transduction signals, 
disruption and assembling of the BBB in pathological conditions Friese  Fugger, 2005. As 
an extension of surveys on neuroaxonal loss and inflammatory demyelination in MS, this 
chapter focuses on the involvement of immune factors in axonal and neuronal 
neurodegeneration and summarizes concepts on immune-mediated axoneuronal 
dysfunction and highlights the potential pathways amenable to therapeutic interventions. 
This chapter will focus on the physiopathology of Multiple Sclerosis with special emphasis 
on glial pathology, information on viral diseases and their relationship in its 
physiopathology, as well as on current therapeutic aspects. 
2. Multiple Sclerosis 
2.1 Heterogeneity in Multiple Sclerosis 
Multiple Sclerosis (MS) is a primary inflammatory demyelinating autoimmune disease 
affecting the CNS and the peripheral nervous system (PNS). Recent results suggest a 
degenerative and hemodynamic profile in this disease, which arises from the evidence of 
early axonal damage Kira, 2007; Porras-Betancourt et al, 2007 and stenotic changes in the 
extracranial vessels that modify the NVU Rose  Carlson, 2007. 
MS is included among the 50 neurological autoimmune diseases that affect approximately 
75 x106 persons in the world Lucchinetti et al, 2000, it is more frequent in women between 
20 and 40 years of age and it constitutes the major cause of neurological disability in young 
adults Martinez et al, 2005; Martinez-Yélamo et al, 1998. 
Neuropathology of MS shows periventricular vascular impairment and leukocyte 
infiltration directed toward the myelin sheath and axon Babbe et al, 2000; Forman et al, 
2006; Jiang & Chess, 2006; Komek, 2003; Neumann et al, 2002. Inflammation leading to 
progressive focal tissue damage and early axonal damage in MS could explain the current 
paradox concerning the temporal sequence of events that mediate axoneuronal damage in 
this disease, as well as the influence of immunomodulating therapy on the rate of relapses 
Coles et al, 2006; Pittock et al, 2004, the persistence of oligoclonal response in the CSF and 
response against neurofilament proteins observed previous to demyelination. These are 
features that support the primary degenerating character of the disease. 
MS is a prototype of neurodegenerative disease affecting primarily the axons and myelin in 
the CNS and the PNS. In spite of the fact that it is a disease which was described more than 
a century ago, the mechanism triggering the immunological reaction against myelin 
antigens remains unknown. Loss of myelin is accompanied by an impairment of nerve 
conduction leading to varied symptoms observed in this disease, that follow the formation 
of demyelinating plaques present in different parts of the brain and spinal cord. 
It has been suggested that MS occurs as a consequence of an inflammatory response induced 
by the interaction of immune, environmental and genetic factors, which lead to 
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demyelination, oligodendrocyte death, gliosis, axonal damage and neurodegeneration. In 
this sense, three aspects are of interest in the neuropathological approach of the disease: 
heterogeneity, viral or immune-environmental hypothesis and the axoneuronal 
degeneration that occurs in early stages of the disease. 
MS displays a great heterogeneity that manifests itself not only in the immunogenetic 
pattern and the clinical forms of presentation, but also in the neuropathology, diagnosis and 
therapeutic response. Different authors have referred to these aspects Bielekova et al, 2005; 
Lim et al, 2005 that could be defined as a) clinical neuropathological heterogeneity and b) 
heterogeneity related to the interpretation of neurobiological findings with respect to the 
diagnosis and clinical course of the disease. 
Heterogeneity due to the influence of genetic and immuno-environmental factors in MS 
The influence of genetic and immune-environmental factors in MS ranges from the 
geographic north-south distribution gradient of the disease, with a higher prevalence in 
developed countries, to the hygienic hypothesis Cabre et al, 2005. 
From a genetical point of view, MS displays a dominant poligenic character, with an 
incidence 20 to 50 times higher in first-degree relatives as compared with the general 
population and more than 100 genes reported. Mirsattari et al, 2001. Nevertheless, the 
highest individual genetic susceptibility is linked to MHC genes, with a distinctiveness for 
HLA DR 15* aplotypes in those exhibiting a more benign course, and HLA DR4 for those 
with a progressive form of the disease. Also, studies in monozygotic twins show a 
concordance of 25% and for dizygotic twins of less than 5%Hillert, 2006; Lisak, 2006; 
Wingerchuck & Kantarci, 2007. 
Other genes reported in MS include transcription genes of MHC class II, complement 
system, cytokines such as IL 17 e IL 17R, IL 1R, TNFp75R, GFAP, TNF, TNF, TNFR, beta 
linfotoxin, adhesion molecules (CD11a, CD18, CD49, 7-Integrin, transcripts for T-cells (TCR 
), NK cells, B cells and proteases involved in antigen processing Camerona, 2009; Gandhi , 
2008. The other hypothesis has strong supporters, due to the autoimmune character of the 
disease and the inflammatory and excitotoxic axonal degenerative reaction underlying the 
demyelinating process. 
Clinical heterogeneity and neuropathology in MS 
Clinical heterogeneity of MS is a consequence of the brain and spinal cord regions where 
plaques are located and the relapse rate - the latter is a very important element in the 
progression of the disease. From a clinical point of view, MS displays 4 clinical forms of 
presentation:1) relapsing-remitting MS, characterized by episodic exacerbations 
(relapses)followed by partial or complete recovery in approximately one month, and 
periods of clinical stability (remission); 2) primary progressive MS that displays a chronic 
progressive course, with no relapses; 3) secondary progressive MS characterized by relapses 
that progress in time, with less exacerbations, more incomplete recovery and irreversible 
disability; and 4) benign MS, which does not display a secondary progressive phase, or does 
not accumulate a significant disability until several decades after the onset of the disease  
Fox et al, 2006; Lee et al, 2007; McDonald et al, 2001. 
In all cases, MS clinical forms overlap, along with the neuropathological patterns described 
for the disease Luchinetti, 2007. In RR-MS an inflammatory pattern prevails, while in the 
www.intechopen.com
 
Recent Advances in Immunology to Target Cancer, Inflammation and Infections 
 
108 
progressive form a degenerative pattern prevails.Changes in the disability scale also 
correspond to clinical findings and imaginological changes in MRI studies. Although other 
factors are involved in the heterogeneous and multiorgan character of MS, all converge with 
the clinical picture to characterize the disease´s behavior individually. 
Clinical and diagnostic heterogeneity 
This aspect refers to the heterogeneity the disease management introduces in the 
interpretation of neurobiological variables, that allow the establishment of criteria from a 
prognostic point of view of the clinical course of MS, specifically for the immunological 
evaluation of CSF and MRI studies Chabas, 2010; Villar, 2005. 
The persistence of an oligoclonal response in the CSF of MS patients indicates the presence 
of a chronic inflammatory process with confirmatory value in this disease. CSF oligoclonal 
banding is an immunological feature not only of MS, but also of other neuroinflammatory 
diseases, including neuromyelitis optica. 
The oligoclonal pattern that prevails in the CSF of MS patients is the presence of oligoclonal 
bands in CSF, but not in serum Andersson, 1994, Correales, 2004, Falip, 2001. It is 
suspected that autoantibodies can exacerbate inflammation and neurodegeneration in 
patients with MS, but which antigens intrathecal oligoclonal IgG recognize and how the 
autoimmune response is induced are still unknown Meinl, 2008. 
Heterogeneity is also associated with specific oligoclonal patterns in specific clinical forms. 
Thus, in the majority of cases, with primary progressive MS, a pattern of CSF and serum 
oligoclonal bands with additional bands in CSF is also found. On the other hand, oligoclonal 
bands directed to myelin lipids have been detected in RR-MS, secondarily progressive MS, 
but not in primary progressive MS Camerona, 2009, Villar, 2005. 
The presence of oligoclonal bands in the CSF has been considered a prognostic tool for the 
clinical management of these patients. Heterogeneity has also been introduced in the 
concordance of CSF analysis and the results of the MRI studies. According to Barkhof's 
criteria, different lesión patterns have been reported in patients positive or negative for CSF 
oligoclonal bands Sospedra, 2009. A lower frequency of infratentorial lesions have been 
reported in the MRIs of MS patients who are negative for oligoclonal bands and a higher 
frequency of juxtacortical lesions in patients with CSF oligoclonal bands. These associations 
are important in order to acquire a better comprehension and management of these patients 
based on the topography of the MRI lesions and their relation with the immunological 
response in the CSF Sospedra & Martin, 2009. 
2.2 Multiple Sclerosis pathology 
2.2.1 Pathogenic mechanisms inducing Multiple Sclerosis 
The oligoclonality and specificity of autoreactive T-cells suggest that myelin protein 
peptides are the activating antigens predominating in MS, whose essential attributes allow 
them to bind the T-cell receptor related with the structure of the lateral chain of the variable 
region of MHC Ag. Actually, it has been stated that the degeneration of the T-cell receptor´s 
ligand specificity is a main mechanism through which infectious agents can cause MS Lee 
et al, 2007; Levin et al, 2010. 
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Among the pathogenic viruses in humans, those which induce persistent infection are 
relevant in MS as the triggering element of the autoimmune process that damages myelin. 
Herpes virus is of particular interest due to its neurotrophism, ubiquitous nature and 
tendency to produce latent recurrent infection. In general, there are 3 mechanisms through 
which viral agents can induce MS: a) molecular mimicry, b) “bystander” activation, and c) 
recognition of cryptic antigens Lu et al, 2011; Levin et al, 2010. 
a. Molecular mimicry 
Considering the viral agents involved in the pathogenesis of MS, 83% of the patients show 
high titers of IgG antibodies for Epstein Barr´s virus Barnett, 2006; Wingerchuck, 2006. The 
molecular mimicry hypothesis is based on the structural similarity between myelin basic 
protein (MBP) peptide and Epstein Barr virus peptide, followed by the activation of 
autoreactive T-cells for myelin and the subsequent loss of the axon´s myelin Haahr & 
Hollsberg, 2006; Maghzi et al, 2010]. 
b. Bystander activation 
Autoreactive T-cells are also activated by unspecific inflammatory events. These events can 
depend on the specific recognition of exposed self-antigens due to tissue damage induced 
by viruses, by the autoreactive immunocompetent cell´s receptor or by independent 
recognition of viral antigens via autoreactive T/B cell´s receptor. In this case, 3 mechanisms 
have been proposed: activation by superantigens, action of pro-inflammatory cytokines 
derived from viral persistence and activation by Toll- like receptors Fujinami et al, 2006; 
McCoy et al, 2006. 
Activation by superantigens 
This mechanism involves the exposure to superantigens (superAgs), toxins derived from 
viral agent induced relapses. This was demonstrated in the EAE model by interaction with 
specific T-cell clones for MBP expressing the V TCR chain Torkildsen et al, 2006. 
Superantigens, are active mitogens, mostly all small basic proteins (20-30 kD), that induce a 
response by binding to the MHC Ags´ lateral part, which is not the usual location. Binding 
does not take place through the polymorphic trimolecular complex or binding Ag site, but 
laterally, at a specific sequence coded by genes of the V TCR chain. After MHC-II and TCR 
bind, aggregation of the receptor and cellular activation follows. Contrary to what 
conventionally occurs, superAgs are not processed by the antigen-presenting cells, nor are 
they presented in the restricted MHC self-antigens context Fujinami et al, 2006; McCoy et 
al, 2006. 
Viral persistence and activation mediated by inflammatory cytokines 
As a consequence of persistent viral infection, virus infected antigen-presenting cells (APC), 
present viral peptides to T CD4+and CD8+ cells together in the context of MHC class 
antigens. The activation of these cells induces the production of INF and the differentiation 
of T-cells via IL-12. T CD4 effector - cells secrete more INF and IL-12 that stimulates the T-
cells differentiation to effectors, secreting more mediators like INF and TNF. Activated 
macrophages also, secrete TNF, nitric oxide and other reactive oxygen species that damage 
the infected cells and other bystander non-infected cells, to be phagocytized by 
macrophages and dendritic cells who process and present self-antigens to T CD4 and CD8 
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autoreactive cells, destroying the tissue´s infected self-cells via perforins, among other 
mechanisms [Lassmann, 2011]. The resulting cellular detritus are captured and processed by 
APC and presented to autoreactive CD8-T lymphocytes who display an autoimmune 
reaction. In this manner, the pro-inflammatory cytokines and chemokines secreted during 
the infection mediate the damage, becoming activators of the T CD8 cells specific for viral 
antigen and autoreactive inductors of the autoimmune process [Pender: 2011]. In this case 
the activation and differentiation of T CD8 cells occurs in an unspecific way Becher et al , 
2007; Haahr & Hollsberg, 2006. 
On the other hand, the CNS antiviral polyspecific immune response in MS, has become a 
potential tool to evidence chronic autoimmune response in these patients Cohrs, 2007. This 
hypothesis has been supported by the reports showing that more than 80% of people with 
MS display humoral intrathecal response against neurotrophic viruses (herpes simplex, 
measles, rubella and varicela zoster, among others). The combined response against these 
neurotrophic viruses in the CNS of MS patients, was coined by Reiber et al as MRZ reaction, 
and many others groups have disagreed on the diagnostic value of this detection from CSF 
analysis in more than 90% of MS patients Colleen et al, 2006; Correales, 2004; Jarius, 2008, 
Jarius et al, 2009; Luchinetti, 2007, since a similar frequency of this autoimmune chronic 
reaction was observed in other neurological diseases Jarius, 2008; Jarius et al, 2009. The 
MRZ reaction has also been reported in NMO patients, although in a lower frequency than 
in MS, and it has been useful to establish a differential diagnosis between both 
demyelinating diseases Jarius, 2008. Other MRZ reaction results were reported in tropical 
regions with variations regarding the previous reports Robinson et al, 2001; Robinson et al, 
2007. In this case, a lower response to rubella virus was observed in the CNS in a smaller 
series of patients regarding varicela zoster and measles virus. The later showed a 
neurotrophic virus response similar to those reported by Reiber et al in German MS persons 
[Reiber et al, 1998]. 
We could think that a reliable interpretation of these last findings probably comes from 
different epidemiological factors in the two countries, or that a previous contact with this 
neurotrophic virus could be necessary for a detectable intrathecal polyspecific MRZ 
antibody response, either by immunization or native infection. In this case, as rubella is a 
mild disease, it may be under-reported, even in areas where reporting has been mandatory 
for years. As it has been previously stated Cooper & Alford, 2001, antibodies to rubella in 
people under 35 years of age is as low as 30% in tropical countries like Trinidad or Panama, 
compared with more than 80% in Europe or the USA Cooper & Alford, 2001; thus, the 
results found in Cuban patients could be comparable for our region without the influence of 
any additional factor. 
Activation by Toll- like receptors 
Although the role of innate – immunity involves native protection and maintenance of 
homeostasis, in some cirscumstances, it could result in a destructive autoimmunity via toll – 
like receptor (TLR), or unspecific mechanisms due to the action of lysozime, lactoferrin, 
oxidative stress or the recognition of molecular structures expressed in non – infected cells 
with an inhibitory effect on the immune response (NK cells, complement proteins and 
family receptors of type C lectins, among others [Frischer; 2009]. The TLR is expressed in a 
wide range of immune and non-immune cells like microglias, oligodendrocytes and 
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astrocytes, which act as centinels, a) by recognition of a conserved molecular pattern 
associated with pathogens or b) generating pro-inflammatory signals that influence the 
adaptative immune response [Chauhan & Marriott, 2007]. 
It is believed that this mechanism initiates the lesion, previously preceded by peripheral 
activation. The LPS binding TLR4 increase cytokine expression and oxygen reactive species 
inducing peripheral autoreactive T cell activation and where an inappropriate TLR signal 
can contribute to MS development [Kielian; 2005]. In this way, the increased expresion of 
TLR on dendritic cells inhibit the immunosupresor effect of regulatory T cells CD4+/CD25+ 
on autoreactive T cells vía IL 6, causing loss of peripheral tolerance. The increase of 
exacerbations around viral infections in MS supports this hypothesis. 
Cryptic Antigens 
Cryptic or sequestered antigens are exposed as a consequence of myelin loss, induce an 
antibody response against them, causing reactive changes within the neuron cellular body 
and axon, blocking the interaction of oligodendrocyte precursors with the axon and 
consequently promoting remyelination and axonal repair Devries, 2006; Magliozzi et al, 
2010. 
2.2.2 Mechanism involving the axoneuronal degeneration in MS  
The investigation of neurodegeneration in MS has received the highest priority in the last 
few years, establishing a multifactorial process involving myelin loss, immune-mediated 
histotoxicity, decreased trophic support, mitochondrial damage, metabolic-energetic 
changes, and altered signalling Ghafourifar, 2008; Klawiter & Cross, 2007; Lindberg et al, 
2008; Sobel, 1998. 
It is commonly accepted that the initial activation of the T cell system takes place in the 
systemic immune compartment outside the CNS, where T lymphocytes encounter a specific 
autoantigen presented in the context of MHC class II molecules Neumann et al, 2002 and 
the simultaneous delivery of additional co-stimulatory signals, such as B7-1 (CD80) and B7-2 
(CD86), on the cell surface of antigen presenting cells. Such autoreactive T cells may reside 
quiescently at this level, until an external trigger - most likely a viral infection- renders these 
cells active to develop their auto aggressive potential.  
The degree of neurological impairment seems to be determined by the extent of axonal loss, 
which is proposed to be the final step in the pathogenesis of the MS lesions. However, so far 
it remains unclear: (a) whether axonal injury is the result of an active destructive process 
targeting the axon; (b) if it occurs as a result of increased vulnerability of demyelinated 
axons or as part of a bystander effect; or (c) if axonal degeneration takes place as a 
physiological response to permanent demyelination inhibiting the extrinsic trophic signal to 
axons Luchinetti. 2007. 
Pathogenic events involved in axoneuronal degeneration  
Two main pathogenic events must be considered as the cause of axoneuronal damage 
leading to irreversible discapacity in MS: a) damage of the myelin oligodendrocytic unit and 
b) the axoneuronal neurodegeneration process.  
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Damage of the myelin oligodendrocytic unit 
Indirect effect of T cells can also mediate damage to the myelin-oligodendrocytic unit. 
Autoreactive T lymphocytes activated from the periphery get into the CNS by degradation 
of the brain vascular endothelial cells. Th1 lymphocytes expressing adhesion molecules such 
as VLA-4 y LFA-1, release cytokines and metalloproteinases MMP2/9 that acting at the BBB 
level, induce an increase of its permeability. The later, linked with a higher integrin 
expression (V-CAM /I-CAM) induced by INF and TNF, facilitate the migration of 
activated T cells into the CNS. Once in the CNS, these activated T-cells release cytokines –
such as INF- which induces activation and differentiation of others autoreactive T cells 
resting in the Tho state, to transform into effector cells, activating microglias, resident 
macrophages in the CNS and T cells, thus contributing to the damage. Recently it has also 
been postulated that T cell regulators can transform into Th-17 effector cells, contributing to 
a major lesional effect on the myelin-oligodendrocytic unit Ishizu , 2010. Figure 2 shows 
the mechanisms related with the indirect effect of T lymphocytes and microglia in the 
damage of the myelin-oligodendrocyte unit.  
 
Fig. 1. Pathogenic mechanism, involving damage of the myelin oligodendrocytic unit. 
Microglia interfere the oligodendrocyte repopulation and mediate their toxicity and death 
with the main intervention of cytokine like IFN and TNF┙. 
Microglia also cause a toxic effect on oligodendrocytes and neurons via extracellular 
glutamate and nitric oxide secretion, while T cells induce direct oligodendrocyte damage, 
via perforine. INF- activated macrophages are also induced to secrete cytokines such as IL-
12 and IL 17 that induce Th1 cells to secrete more INF. INF then induces the expression of 
Fas molecules on the oligodendrocyte surface promoting a Fas-Fas ligand interaction, 
followed by oligodendrocyte apoptotic death, Fig 1. Thus, the microglia, main mediator of 
glial –neuron interaction becomes a binding point between the innate and adaptative 
immune systems. In acute inflammation, microglia act as antigen presenting cells (APC), 
and contribute to antibody clearance and elimination of myelin detritus after clinical relapse. 
However, during the chronic phase of a pathological condition like MS, this cell type 
contributes to irreversible damage. Glial-derived INF, also interferes with the vitality, 
recruitment and function of OPC, interfering with complete remyelination at lesion sites.  
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Fig. 2. Indirect T cell effect, on the myelin-oligodendrocytic unit in MS. Microglia also, 
causes a toxic effect on oligodendrocytes and neurons via extracellular glutamate and nitric 
oxide secretion. Th1: T-helper-1 cells. 
 
Fig. 3.Axonal damage mediated by mechanisms independent of active inflammation in MS. 
OG; oligodendrocyte, OPC: oligodendrocyte precursor cells. 
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On the other hand, damage to the myelin-oligodendrocytic unit occurs as a consecuence of 
an increased vulnerability of demyelinated axons to immune attack, a reduced trophic 
support, since myelination provides an extrinsic trophic signal to axons. Fig 3 shows the 
mechanisms leading to axonal damage independent from active inflammation: loss of 
trophic factors and ionic and energetic unbalance, Fig 3.  
Neuronal damage in MS results from two insults: on one side mediated by microglia, via IL 
1beta, TNF, IL 6 and NO, all neurotoxic to neurons which are functionally compromised 
by hypoxic damage, and on the other side due to an excess of extracellular glutamate, 
oligodendrocyte toxicity, and axonal loss. Gene transcripts for TNF and IL 6 with an impact 
on the pathophysiology of MS have been identified in the margins and center of the active 
lesions, but not in the inactive lesions Jack et al, 2007]. 
Axoneuronal degeneration in MS 
Loss of trophic support in MS pathophysiology: Reduced inflammation occurring during 
the course of chronic demyelination suggests the existence of mechanisms not related to 
active inflammation as being responsible of continuous axonal loss and progressive and 
irreversible inability. It has been acknowledged that this is due to the loss of trophic support 
derived from oligodendrocyte damage, which is necessary for axonal survival independent 
from compact myelin (Fig 4).  
 
Fig. 4. Mechanism involved in the axoneuronal degeneration process. Neuroaxonal loss 
represents the major pathophysiological element correlating with clinical disability. The 
figure summarizes the mechanisms causing demyelination and axoneuronal degeneration in 
MS and their combined contribution to disease progression and irreversible inability. 
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Ionic unbalance in MS pathophysiology: Ionic unbalance –as a result of compensatory 
changes to restore nervous conduction following demyelination- can induce long term 
axonal degeneration. Therefore, the redistribution of Na channels on demyelinated axons 
restores the action potential, neuronal function and increases Na and ATP influx, via the 
Na/K ATPase pump to maintain the ionic gradient, which is necessary for 
neurotransmission. Both processes are highly energy consuming, leading to energetic 
unbalance, altered axonal ion concentrations and subsequent neurodegeneration (Fig4). 
Antibodies to Cytoskeletal Proteins: Neurofilaments are a group of cytoskeletal proteins 
expressed in neuronal cells and axons. Neurodegenerative disorders like Alzheimer’s 
disease and Parkinson’s disease are characterized by accumulation of NF proteins leading to 
abnormalities in axonal transport and an impending neuronal loss [Amor et al, 2010; 
Arumugam et al, 2008]. Antibodies to axonal cytoskeletal proteins may be markers of axonal 
damage, as well as important contributors to neurodegeneration and clinical disability in 
MS. CSF levels of antibodies against the NFL correlate with disease duration, clinical 
disability, IgG index, and the degree of cerebral atrophy measured by MRI [Bartos et al, 
2007; Eikelenbom, 2003]. Although elevated levels of NFL-specific antibodies are present in 
sera of patients with PP-MS, these antibodies are also increased in sera of patients with other 
neurological diseases [Bartos et al, 2007; Huizinga, 2008]. 
Although there is no confirmed evidence to establish that antineurofilament antibodies 
themselves contribute to mayor neuroaxonal damage, experimental models provide 
supportive evidence [Amor et al, 2010]. Immunization of mice with NFL triggers the 
development of a CNS disease characterized by axonal damage, paralysis, and spasticity 
[Huizinga et al, 2008]. Furthermore, microinjections of anti-kinesin or anti-dynein antibodies 
cause impairment of the anterograde and retrograde NF transport in cultured neurons 
[Theiss et al, 2005] and induce the formation of long and branched mitochondrial structures 
redistributed to the nuclear periphery. These intracellular changes are associated with 
altered calcium homeostasis, apoptosis, and neurodegeneration [Arumugam et al, 2009]. 
Antibodies to neurofilaments and possibly to other cytoskeletal proteins are produced 
during tissue damage in MS. Experimental data support that these antibodies may gain 
access to their intracellular target and cause changes in axonal transport, mitochondrial 
distribution and calcium homeostasis, and thus contribute to apoptosis and 
neurodegeneration [Vishkina & Kalman, 2008]. 
Criteria based on evidence regarding the role of Ab-mediated autoreactivity to 
neurofilament proteins in MS has been controversial Silber et al, 2002; Bartos et al, 2007; 
Bartos el al, 2007a; Bejartmar & Trapp, 2003; Semra et al, 2002; Eikelenboom et al, 2003. 
Bartos et al for example, detected increased intrathecal IgG and IgM antibodies against the 
medium subunit of neurofilaments (NFM) in patients with all subtypes of MS Bartos et al, 
2007; Bartos et al, 2007a while Silber et al [2002 maintained the relevance of autoantibody 
to NFL in CSF as progression markers in MS. Unexpectedly, anti-NFM antibody levels 
appeared to be higher in the serum than in CSF, possibly related to NF antigen leakage from 
the CNS to the peripheral blood, or to the higher concentration of plasma cells in the blood. 
Alternatively, anti-NFM antibodies may be triggered by exogenous antigens and molecular 
mimicry in the peripheral blood Bartos et al, 2007; Bartos et al, 2007a; Bejartmar et al, 2003; 
Eikelenboom et al, 2003; Semra et al, 2002; Silber et al, 2002. 
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Besides these considerations, the evaluation of axonal markers from CSF analysis, have 
shown different results; some experiences considering these biomarkers promissory for 
monitoring progression andor relapsing rate in MS. So, a study in patients published by 
Eikelenboom et al, reported a significant correlation between intrathecal production of 
NFLP antibody in CSF and cortical atrophy and more recently a significant relationship 
between NFLP antibody index and relapsing rate was observed in patients bearing MS 
Eikelenboom et al 2003; Robinson, 2010. Fig 5 shows a study conducted in a group of 26 
Cuban MS patients with different clinical forms of the disease. The evaluation of Ab 
reactivity to NFLP in CSF was significantly correlated with the relapsing rate, denoting an 
association between both clinical and biological parameters. These results are interesting 
since they show another aspect of the idiotipic response in MS, and its possible insertion not 
only from the view point of the pathogenic mechanism of the disease, but also as a useful 
clinical tool, at least to predict or monitor treatment response.  



















 AINFLP:Relapsing rate:  r
2 = 0,3089; p = 0,0391
Relapsing rate = 3,0344+1,5814*x; 0,95 Conf.Int.
 
Fig. 5. Statistical analysis between AINFLP and relapsing rate in MS patients showed a 
significant correlationship between both parameters. * Spearman´s correlation test, p0.05. 
AINFLP: Antibody index to neurofilament light protein. AINFLP: NFLP CSF/NFLP Serum / 
IgG CSF/IgG serum. 
2.3 Autoimmunity contributing to glial pathology in MS 
Neurodegeneration in MS occurs in response to a multifactorial process involving loss of 
myelin protection by immune-mediated histotoxicity, decreased trophic support, 
mitochondrial damage, metabolic changes and altered signaling Ghafourifar et al, 2008; 
Lindberg et al, 2008. Nevertheless, different neuronal targets have been identified as 
causing neuronal dysfunction, following a humoral immune mechanism in MS which can be 
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classified as neuronal surface molecules, intracellular enzymes, signaling molecules and 
chaperones, nuclear antigens and cytoskeletal protein among others (Vyshkina & Kalman, 
2008|. On the other hand, it has been suggested that microglial responses are tailored in 
regional and insult-specific manners [Carson et al, 2007]. The most recognizable role of 
microglia in brain defense is as a scavenger of cellular debris by phagocytosis, as occurs in 
the event of infection, inflammation, trauma, ischemia, and neuronal death [Kraft & Harry, 
2011]. However, it is well known that, not only do microglia dynamically survey the CNS to 
clear damaged cellular debris, but they are also capable of initiating a rapid and specific 
response to subtle changes in the microenvironment. Different types of neuronal pathology 
and other activating stimuli clearly elicit differing responses from brain-resident microglia 
[Colton & Wilcock, 2010; Rivest, 2009], evidencing the autoimmune process that leads to 
brain damage as occurs in MS. 
B cells and autoimmunity in MS 
B cells are involved in multiple immune pathways including the presentation of antigenic 
determinants and the expression of costimulatory signals for T lymphocytes, 
immunoglobulin production, secretion of cytokines, and recruitment of T cells into the CNS. 
The B-cell lineage is represented by B lymphocytes (CD19þ, CD138), plasma blasts (CD19þ, 
D138þ), and plasma cells (CD19_, CD138þ; all detectable in CNS and CSF. In MS most of 
these cells express memory phenotypes, CD27þ positive. A relevant contribution of humoral 
autoimmunity in myelin loss has been proposed in demyelinating diseases with a 
prominent intervention of complement molecules and Ab itself [Lucchinetti et al, 2000; 
Serafini et al, 2010]. Thus, immunological and molecular results have repeatedly been 
reported by differents groups in this field, all of them directed towards the characterization 
of the cellular arm of autoimmunity.  
Mechanisms leading to autoimmune B-cell activation may be initiated by CD4 T helper type 
2 (TH2) lymphocytes and their soluble inflammatory products (eg. interleukins 4, 5 and 13) 
followed by an antigen-specific expansion of clones either in the peripheral circulation or in 
the damaged CNS tissue, where intracellular proteins are released. As it was expressed 
earlier in this chapter, bystander activation describes a non-antigen-specific activation of T 
or B cells usually mediated by soluble inflammatory products of nearby immune cells, while 
the humoral immune system appears to be more successful in breaking anti-neuronal 
tolerance than the cellular system, and has greater pathogenic significance supporting the 
involvement of the humoral immune response in MS-related neurodegeneration [Huizinga 
et al, 2008]. 
From a molecular view point, data also support the involvement of B lymphocytes and their 
products in MS. Intrathecal production of immunoglobulins with an oligoclonal 
electrophoretic distribution pattern is a hallmark of the disease. Clonally expanded 
autoreactive B cells in the CSF and CNS have increased VH mutation rates concentrated in 
the complementarity determining regions. VH sequences expressed in plaques are absent in 
the peripheral blood Owens et al, 2001. B-cell heavy and light chain editing, a mechanism 
to prevent autoimmunity by the replacement of elements in rearranged immunoglobulin 
genes after the re-expression of recombination activating genes —RAG1/RAG2, is 
inefficient in MS, a fact which is suggested by the detection of autoreactive B cells with 
unsuccessfully edited receptors in the CSF Lambracht-Washington et al, 2007; O’Connor et 
al, 2007 These observations suggest that CNS antigen-specific and clonally expanded B cells 
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present in CNS and CSF of MS patients exhibit complex molecular characteristics and 
intraclonal diversity. 
Neuroaxonal targets of humoral autoimmunity in MS and EAE have been identified in the 
CNS during the process of demyelination. Immunoglobulins produced by activated B cells 
in the CNS and CSF target numerous self-antigens including components of CNS myelin 
such as myelin basic protein, proteolipid protein, myelin-associated glycoprotein, and 
myelin oligodendrocyte glycoprotein Dutta & Trapp, 2007. A great number of papers 
discuss the involvement of myelin-specific antibodies in the development of demyelination 
and disease progression and although not uniformly, the use of some of these antibodies as 
biomarkers is accepted as a support to the diagnosis or to monitor disease activity and 
course Amor et al, 2007; Lutterotti et al, 2007 
Anti-Neuronal Antibodies in MS 
Antibodies to a variety of intracellular molecules including enzymes, signaling molecules, 
HSPs, and nuclear proteins are detected in MS and other inflammatory and neurological 
disorders. The production of these antibodies may be related to bystander immune 
activation and epitope spreading during tissue injury, as was referred before, although their 
pathogenic significance remains uncertain in some cases. 
Antibodies Targeting Neuronal Cell-Surface Molecules: Neuronal cell-surface antigen 
molecules in the surface membrane of myelinated axons are normally hidden from the 
immune system, and only become exposed after demyelination becoming antigenic and 
inducing the production of neuron-specific antibodies. IgG and IgM antibodies binding to 
the surface of a neuronal cell line were found in 70% of sera from patients with secondary 
progressive (SP)-MS and in 25% of sera from patients with relapsing-remitting (RR)-MS 
Kraft & Harry, 2011 . This finding may indicate the spreading of autoimmunity to 
neuronal antigens as a consequence of CNS expansion and tissue damage.  
Axolemma-enriched fractions: Antibodies to axolemma-enriched fractions (AEF) of the CNS 
are also present in CSF and sera of MS patients, [Zaffaroni, 2003].From in vitro assays, there 
is evidences that these antibodies damage neurites and prevent neuronal outgrowth. The 
production of anti-axolemma and anti-myelin IgGs appears to be independent. Criteria to 
consider antiaxolemmal IgG antibodies as markers of axonal damage are based on these 
observations [Zaffaroni, 2003]. 
Neurofascin: One of the targets in antibody-mediated axonal injury is the cell-adhesion 
molecule neurofascin. The 186 kDa neuronspecific isoform of neurofascin (NF186) is 
involved in the clustering of voltage gated Na channels at Ranvier´s nodes, while the 155 
kDa glial-specific isoform (NF155) is required for the proper assembly of paranodal junction, 
targeting the interaction sites between myelin and axon. Early in the disease course and 
preceding demyelination, changes in the distribution of NF155 have been observed in MS 
lesions [Vyshkina1 & Kalman, 2008]. Maier et al [2007] showed that the NF155-levels were 
reduced, suggesting that NF155 is subject to protein degradation in the lesions. On the other 
hand, studies in sera showed levels significantly higher in patients with chronic progressive 
forms of MS compared to other inflammatory neurological diseases. At the same time, 
studies in vitro showed that antibodies to neurofascin inhibit axonal conduction and that 
NF155-specific antibodies cross-react with NF186-transfected cells at the nodes of Ranvier 
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possibly initiating axonal injury and accelerating disease progression [Mathey et al, 2007]. 
Neurofascin-specific antibodies can also inhibit remyelination by binding to NF155 
expressed on the surface of oligodendrocytes. In vivo experiments revealed that antibodies 
to neurofascin and complement can selectively target nodes of Ranvier, cause axonal injury, 
and trigger disease exacerbation in EAE [Mathey et al, 2007]. 
Anti ganglioside antibodies: It is well known that gangliosides are glycolipids with sialic 
residues in the outer layer of cell membranes, particularly enriched in the membranes of 
neurons. Experimental data reveal that antiganglioside antibodies can disrupt the BBB, 
create neuromuscular block by binding to neuronal gangliosides at the neuromuscular 
junction and inhibit axonal regeneration after peripheral nerve injury in mice [Amor et al, 
2010],. Increased levels of anti-GM3 (monosialoganglioside) antibodies can be found in sera 
of a great proportion of patients with progressive forms of MS (56.3%) in primary 
progressive (PP)-MS and in 42.9% of SP-MS vs 2.9% in RR-MS and 14.6% in OND. Anti-GD2 
(disialo-ganglioside)-like IgM autoantibodies were detected in sera of 30% of MS patients, 
and a positive correlation of anti-GD2-like IgM reactivity with neurological disability was 
observed [Kanda et al, 2000]. The increased prevalence of GD2-specific IgM antibodies in SP-
MS (47.8%) compared to RR-MS (24.2%) and PP-MS (26.7%), also suggests the involvement 
of these antibodies in inflammation-induced neurodegeneration [Marconi et al, 2006]. It 
should be emphasized; that it is not clear whether anti-ganglioside antibodies can cause or 
result from axonal damage, and whether they may definitely function as putative markers 
of neurodegeneration in MS. 
In general, these data suggest that antibodies specific to neuronal cell-surface molecules are 
produced during demyelination, and that they may themselves contribute to glial pathology 
or axonal injury in MS. These antibodies can activate complement and exert cytotoxicity, 
provide binding sites for the Fc receptors on macrophages and microglial cells, interrupt 
axon–myelin interaction, inhibit axonal conduction and outgrowth, disrupt the BBB, and 
alter oligodendrocyte functioning. Correlation of the antibody titers with the severity of 
disability offers an opportunity of using these neuronal cell-surface antibodies as 
biomarkers. 
Antibodies to Intracellular Molecules: Arrestins, glutamate decarboxylase and nuclear 
antigens 
MS patients show a high prevalence of autoreactivity to intracellular antigens such as 
neuron-specific enolase (metabolic enzyme), b-arrestin and retinal arrestin among others. 
So, antibody reaction to arrestins, a family of multifunctional, intracellular proteins that 
regulate signal transduction and the activity of G-protein-coupled receptors, has been 
reported in MS; while b-arrestin-1 enhances the expression of antiapoptotic Bcl2 that may 
control the development of both MS and EAE. Anti-b-arrestin-specific antibodies and 
antibodies to retinal arrestin can be found in sera of patients with MS. Gorczyca et al, 2004. 
B-Arrestin-1-knockout mice are more resistant, and b-arrestin-1 transgenic mice are more 
susceptible to EAE Frederick & Miller, 2007; Shi et al, 2007. 
Immunity to glutamate decarboxylase (GAD), an enzyme that converts glutamate into the 
inhibitory neurotransmitter aminobutyric acid (GABA), can also be detected in MS. GAD is 
expressed in various cell types including neurons, and its activity is reduced in sera of MS 
patients. Serum anti- GAD65 antibodies are present in 10% of MS patients Hermitte et al, 
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2000. Anti-GAD antibodies have also been associated with systemic autoimmune disorders, 
such as type 1 diabetes, although without a clear understanding of the pathogenic 
significance Taplin & Barker, 2008. Elevated antinuclear antibodies (ANA) in sera of MS 
patients have been reported at varying frequencies (2.5–81%) depending on the 
methodological approaches Ferreira et al, 2005; Roussel et al, 2000. In contrast, the ANA 
titers are low (between 1:40 and 1:100) in sera of MS patients, who also often have low-
affinity IgG antibodies to multiple other nuclear and cytoplasmic epitopes.  Ferreira et al, 
2005; Roussel et al, 2000; Lu & Kalman, 1999. These data suggest that detection of ANA and 
related antibodies in MS may result from a nonspecific immune activation. 
Furthermore, these observations support that B cells may contribute directly or indirectly to 
MS development. Removal of immunoglobulins from the peripheral blood by 
plasmapheresis appears to be beneficial in the subgroup of patients with type II lesions 
[Keegan et al, 2005] and depletion of CD20 B cells by rituximab results in a significant 
reduction in the number of enhancing MRI lesions. The latter intervention, however,does 
not exert its beneficial effects by directly affecting the immunoglobulin pool, but by 
depleting memory B cells and altering antigen presentation, T-cell activation, or T-cell 
recruitment into the CNS [Hauser et al, 2008].  
Autoimmunity and Glutamate-Mediated Neurotoxicity  
Glutamate is a neurotransmitter released by neurons into the synaptic space where it binds 
to its postsynaptic receptors. Elevated levels of extracellular glutamate can lead to the death 
of neurons, astrocytes and oligodendrocytes Matute et al, 2006. Excitotoxic tissue damage 
mediated by glutamate has been described in a number of neurologic diseases (eg stroke, 
traumatic injury, neurodegeneration) including MS Vercellino et al, 2007. 
Glial cells and neurons express various types of glutamate excitatory amino-acid 
transporters (EAAT1–EAAT5). The reuptake of glutamate appears to be impaired in MS due 
to the downregulation of EAAT1 and EAAT2 molecules in white matter and cortical 
lesionsVercellino et al, 2007. Glutamate levels in the CSF are higher during relapses than 
remissions, and correlate with disease severity Sarchielli et al, 2003.) These observations 
suggest that inflammation upsets the balance of glutamate release and re-uptake, and the 
excessive glutamate may escalate tissue injury in MS. 
Glutamate toxicity may be further enhanced by altered receptor expression and 
signaling.Two main subtypes of glutamate receptors have been identified: ionotropic, 
coupled directly to membrane ion channels; and metabotropic, coupled to G proteins. The 
ionotropic receptors are divided into three subtypes based on their selective agonists: N-
methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), 
and kainate Lipton & Rosenberg, 1994. An elevated expression of subunit 1 of AMPA 
receptor (GluR1) on oligodendrocytes at the borders of active plaques, and subunit 3 of 
AMPA receptor (GluR3) and metabotropic glutamate receptors (mGluR) on reactive 
astrocytes in MS lesions have also been reported. Activated microglia and macrophages are 
immunopositive for NMDA receptor subunit 1 (NR1) in plaques and may also play a role in 
Ca-dependent injury of oligodendrocytes and neurons. NMDA receptor antagonists, 
memantine, amantadine, and MK-801 reduce neurological deficits in EAE, and the blockade 
of AMPA receptors by antagonists, also ameliorate clinical signs of EAE. Bolton & Paul, 
1997; Smith et al, 2000; Stys & Lipton, 2007; Wallstrom 1996. 
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Antibodies targeting glutamate receptors may have agonist or antagonist effects. Agonists 
usually cause excitotoxicity and complement-mediated cell death Groom et al, 2003. Anti-
GluR3 antibodies are implicated in epilepsy syndromes but not in MS. In summary, these 
observations suggest that glutamate homeostasis is being upset in inflammatory lesions of 
MS, where the concentration of glutamate is increased, at least in part, due to a decreased re-
uptake. In addition, anti-glutamate receptor antibodies are associated with inflammatory 
and neurodegenerative disorders, like MS, often correlating with clinical improvement. 
Induction of Central Nervous System Autoimmunity by Th17 lymphocyte in MS 
T-helper cells classically divide into two functional subsets including: Th1 and T-helper-2 
(Th2); each one with a distinct activity of transcription factor and pattern of cytokine-
secretion phenotype [Mosmann et al, 1986.]. Th1 cells produce IFN-Ǆ, TNF-ǃ and 
interleukin-10 (IL-10), and mediate cellular immune responses against tumor cells, 
intracellular viruses and bacteria via macrophages and cytotoxic T-cell activation. In 
addition, Th1 cells drive cell-mediated response leading to tissue damage and drive 
humoral immune responses to Ig2a subclasses. Innate immune cells, through STAT6 signals, 
secrete IL-4 that induces the transformation of naıve CD4+ T cells into Th2 cells, leading to 
the expression of transcription factor GATA3. This cascade of events in turn results in the 
production of IL-4, IL-5, IL-13, IL-21 and IL-31, important for host defense against helminths 
and contribute to the pathogenesis of asthma and allergy [Monteleone et al, 2008; Steinman, 
2007; Wilson et al, 2009]. Other T-cell subsets that co-express CD4 and CD25 are Th3 cells, or 
regulatory T (TREG) cells, which regulate both Th1 and Th2 cell function, and maintain 
homeostasis of the immune system [Vojdani & Lambert, 2011]. TREG cells can develop from 
thymic CD4+ T-cell precursors in the presence of IL-2 and TGF- ǃ, which are termed natural 
TREG cells. TREG cells produce low levels of IL-2 and IFN-Ǆ, but produce high levels of IL-
10, IL-35 and TGF-ǃ, suppressing immune responses to self-antigens and preventing 
autoimmune disease by two different immunoregulatory immunosuppressive or 
antiinflammatory cytokines, IL-10 and TGF-ǃ , Fig 6. 
More recently, a specific T-cell subset, termed Th17 cell, that secretes a cytokine called IL-17, 
has been identified. This cell develops from naıve CD4+ T cells in response to IL-6, IL-23, 
TGF-ǃ and IL-1ǃ. IL-6 and IL-23 activate STAT3, which increases the expression of RORǄt 
and RORǄ transcription factors, promoting the expression of IL-17A, IL-17F, IL-21 and IL-22. 
These cells, important for host defense against extracellular bacteria, are also involved in 
mediating autoimmune diseases [Chung & Dong, 2009; Stockinger & Veldhoen, 2007. The 
immunopathogenic activities of Th17 cell in inflammation and autoimmunity has been 
linked to a growing list of cancers, autoimmune and inflammatory diseases such as 
rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, asthma, psoriasis, 
systemic sclerosis, chronic inflammatory bowel disease and allograft rejection [Chung & 
Dong, 2009; McGeachy et al, 2009; Steinman, 2007]. 
Th1 and Th2 effector molecules antagonize the development of Th17 cells, which are 
responsible for destructive tissue pathology in autoimmune diseases including 
neuroinflammation; whereas, naıve CD4 cells in the presence of IL-12 and transcription 
factors, such as T-bet and STAT4, become Th1 cells, which express IL-12R and produce IFN-
Ǆ. Naıve CD4 cells in the presence of IL-4, GATA-3 and STAT6 become Th2 cells, which 
produce IL-4. Finally, naive CD4 cells in the presence of TGF-ǃ, IL-23 and transcription 
factor RORǄt become IL-17-producing Th17 cells [Batten et al, 2006; Cheung et al, 2008]. 
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As it was previously mentioned, the pathogenic contribution of Th1, Th2 and Th17 
lymphocytes to autoimmune disorders has been reported both in systemic and in 
neurological diseases Zheng et al; 2007. IL-17-producing T-helper cells play an important 
role in the induction of neuroimmune diseases, like MS and its animal model called 
experimental autoimmune encephalomyelitis (EAE) [Iwakura & Ishigame, 2006.]. This 
observation is based on the detection of IL-17 levels in both the plaques and cerebrospinal 
fluid of MS patients [Ishizu et al, 2005].  
It has been established that IL-17 is a proinflammatory cytokine that stimulates epithelial, 
fibroblast and endothelial cells to produce other inflammatory chemokines and cytokines, 
including macrophage inflammatory protein (MIP)-2, monocyte chemoattractant protein 
(MCP-1), granulocyte-colony stimulating factor (G-CSF) and IL-6 and synergizes with IL-1ǃ 
and TNF-ǂ, to induce more chemokine expression [Vojdani & Lambert, 2011]. 
Also, microglia is known either as antigen presenting cells and effector cells and is involved 
in inflammatory demyelination of the CNS. It was shown that treatment of microglia with 
IL-17 upregulated microglia production of IL-6, MIP-2, nitric oxide, neurotrophic factors 
and adhesion molecules. In a similar way IL-1ǃ and IL-23 may induce microglial IL-17 
production, contributing to neuroimmune pathology in MS [Kawanokuchi et al, 2008]. An 
additional support to this hypothesis came from the experience in mice injected with 
specific antibodies against IL-17, which resulted in inhibition of chemokine expression, 
whereas overexpression of IL-17 in lung epithelia resulted in chemokine production and 
leukocyte infiltration [Vojdani & Lambert, 2011].  
In MS, the location and distribution of CNS lesions under the influence of genetic 
susceptibility is determinant for clinical outcome and disease course and suggests that T-cell 
immune response specificity influences the sites of inflammation. A recent study published 
by Stromnes et al in 2008, demonstrated that T-cells specific to MBP epitopes generate two 
different populations of helper cells, Th17 and Th1 [Stromnes et al, 2008]. Notably, the Th17 
to Th1 ratio of infiltrating T-cells determines that inflammation in the brain parenchyma 
occurs when the ratio of Th17 to Th1 cells is much greater than one, triggering a 
disproportionate increase of IL-17 in the brain that results in inflammation, Fig.6. At the 
same time, these results indicate that Th17, Th1 and their ratio, are main mechanisms 
regulating cell infiltration into the brain parenchyma.  
Stromnes´ group also considered that a differential regulation of inflammation in the brain 
with a Th17:Th1 ratio >1, and in the spinal cord with a Th17: Th1 ratio <1, indicates that Th1 
cells play a significant pathologic role in spinal cord autoimmunity [Stromnes et al, 2008]. It 
was concluded that IL-17 produced by Th17 cells is the major regulator of CNS 
autoimmunity. So, IL-17, deemed as the most pathogenic cytokine in inflammatory 
neuroimmune and autoimmune disorders, induces the activation of matrix 
metalloproteinase-3 (MMP-3) and recruits neutrophils to the site of inflammation, which 
also activates MMPs, proteases and gelatinases, contributing to BBB breakdown and a 
further enhancement of neutrophil recruitment. This increase in protease activity, which 
attracts a significant number of monocytes and macrophages to the inflammatory sites, with 
a subsequent citokine secretion and glial activation, reinforces the eventual myelin and 
axonal damage [Tester et al, 2007]. Thus, it is possible to consider that under CNS 
inflammatory conditions, microglia, which act as antigen presenting cells, produce IL-1ǃ 
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and IL-23 and act in an autocrine manner, via IL-17 expression in microglia and IL-17-
induced activation of MMP-3, contributing to neuroimmune pathology in MS.  
 
Fig. 6. The role of Th17 lymphocytes in the pathogenesis of inflammatory and 
neuroimmunological disorders. Environmental factors’ induction of inflammatory response, 
production of cytokines and increase in the number of Th17 positive cells in circulation. 
Expression of IL-17 and IL-22 receptors on blood-brain barrier endothelial cells result in the 
binding of Th17 cells to BBB tight junctions. This disrupts the tight junctions, and the Th17 
cells then transmigrate across the BBB, setting the stage for the killing of neurons by the 
release of granzyme B. CAM protocols may be used to block the inflammatory cascade 
induced by infection. CAM: Complementary alternative medicine, BBB; blood brain barrier. 
Taken from: The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part II. 
In Hindawi Publishing Corporation Evidence-Based Complementary and Alternative 
Medicine, Volume 1-7, 2011. 
Induction of BBB Disruption and Neuroinflammation mediated by IL 17 in MS  
The BBB is composed of two layers: the microvascular endothelial cells and the glia limitans 
formed by glial foot processes [Maes et al 2007]. The perivascular space between the 
endothelial cells and astrocytes is populated by macrophages, which behave like immature 
dendritic cells [Vojdani & Lambert, 2011]; thus factors able to open the epithelial barrier will 
destroy both the BBB and neural tissue [Maes et al 2007; Maes et al, 2008].  
Since microglia play a significant role in MS, to further strengthen the role of IL-17 in CNS 
inflammation, microglia were treated with IL-17. Treatment with IL-17 upregulated the 
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microglial production of IL-6, MIP-2, nitric oxide, adhesion molecules and neurotrophic 
factors [Kawanokuchi et al, 2008]. Since it is known that IL-17 can be secreted by microglia 
in response to IL-1ǃ or IL-23, these results strongly suggest that the cells co-expressing IL-17, 
IL-22 and granzyme B through the action of IL-17 and IL-22, play a significant role in the 
induction and breach in the BBB and its permeabilization to circulating CD4+ lymphocytes 
and soluble molecules resulting in CNS inflammation [Vojdani & Lambert, 2011]. The role of 
Th17 lymphocytes in the pathogenesis of inflammatory and neuroimmunological disorders 
is shown in Figure 6. This role of Th17 cells and the IL-17 produced by them in 
neuroinflammation could make these novel CD4 cells a suitable target for treatment in 
demyelinating diseases like MS. 
Therapies towards BBB repair and the inhibition of lymphocyte transmigration can reduce 
neuro-inflammation, and at the same time, could be relevant since resident microglia and 
astrocytes, play an important role in the initiation and progression of immune responses 
induced by pathogen invasion or their antigens [Chauhan and Marriott ; 2007]. So, infections 
associated with high levels of inflammatory cytokines including IL-1ǃ, IL-6, TNF-ǂ and IL-17 
in the CNS may result in neurological dysfunction. In this case, microglia and astrocytes via 
TLR and nucleotide-binding domain promote the recruitment and antigen-specific 
activation of infiltrating leukocytes [Rock et al.; 2004; Kielian; 2005]. 
Accumulated evidence has shown that substance P (SP), the most abundant tachykinin in 
the brain, also plays an important role in the inflammatory immune responses at peripheral 
sites [Vojdani & Lambert, 2011]. Neuropeptide SP, with its high affinity receptor NK-1R is 
expressed on microglia and can also modulate the function of myeloid cells, such as 
dendritic cells and macrophages via a high affinity receptor called neurokinin-1 (NK-1). SP 
with NK- 1R activate the transcription factor NF-κB, which facilitates the production of key 
proinflammatory cytokines such as TNF-ǂ, IL-6 and IL-17, and also reduce the production of 
immunoregulatory cytokines (TGF-ǃ, IL-10) by macrophages; thereby further exacerbating 
inflammation [Vojdani & Lambert, 2011]. The mechanism of bacterial antigens inducing the 
neuronal SP production and it´s binding to SP receptors, result in cytokine production and 
brain inflammation. Furthermore, products, such as SP receptor antagonists for the 
inhibition of NF-κB, or minocycline, ǂ-Lipoic acid, resveratrol [Aebischer & Kato; 2007; 
Lampl et al, 2007] or quercetin [Sternberg et al, 2008], which are known to be effective in the 
repair of BBB damaged by infections, may represent important new therapeutic strategies to 
combat potentially disabling consequences of inflammation within the brain. 
2.4 Current perspective on treatment in MS  
Further evidence to support the importance of neurodegeneration in MS is obtained from 
clinical data showing only a partial success of the available disease-modifying drugs 
(interferons, Glatiramer Acetate, monoclonal antibodies to antigenic determinants expressed 
on T lymphocytes, among others), which impede activation and migration of inflammatory 
cells via the BBB, but have no direct effect on the degenerative processes in the CNS. Antel 
& Miron, 2008; Bergamaschi et al, 2006; De Jager , 2007; Miron et al, 2008; Weinstock-
Guttman, 2006. 
The research community has clarified the underlying biology of MS and shown great 
promises for developing an improved therapy. Areas of research that hold promise in the 
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near future include: 1) the development of drugs that block the movement of myelin-
attacking T cells from the bloodstream into the brain, 2) engineering drugs that specifically 
inhibit the damaging T cells or antibodies, 3) finding approaches that promote 
remyelination (myelin ro treatment in MS repair), which may allow individuals to regain 
function and 4) studies of MRI, immune, and genetic variables that improve our ability to 
predict the disease course, and tailor or engineer therapy to individuals with MS.  
Trials of stem cell transplantation, with the goal of repopulating oligodendrocytes, are 
underway in people with MS. Remyelination may also be promoted by blocking leucine rich 
repeat and Ig domain-containing, Nogo Receptor-interacting protein 1 (LINGO-1), a protein 
on the surface of neurons that inhibits differentiation of precursor oligodendrocytes into 
mature cells. Antibody blockade of LINGO-1 has shown promise in an animal model of MS 
[Loeb, 2007]. Neurotrophins are protein factors produced by CNS cells that support 
neuronal growth, survival and differentiation [Azoulayet al, 2008]. In MS, secretion of the 
neurotrophin brain-derived neurotrophic factor is low and dysregulated [Mi et al, 2009] and 
BDNF is therefore also being considered as a therapeutic target. Current MS therapeutics are 
moderately effective for modifying disease during its relapsing-remitting phase. There are a 
number of oral and parenteral agents that target developing inflammation, and several are 
likely to be approved for treatment of RRMS within the next few years. These therapies will 
likely more effectively control RRMS but will also carry greater known and, as yet, 
unknown safety risks. These risks and benefits will have to be weighed carefully against the 
efficacy and proven safety of the IFNs and Glatiramer acetate. Furthermore, none of the 
anti-inflammatory therapies currently in late stage of development are likely to benefit 
patients with SPMS and PPMS. Development of effective neuroprotective and 
neurorestorative therapies are needed in order to benefit patients with progressive MS.  
3. Conclusion 
Since MS shows a great heterogeneity, the influence of multiple etiopathogenic factors could 
be considered as the main cause of this behavioral pattern. Nevertheless the well established 
hypothesis on the aetiology and pathogenic mechanisms described for this disease are not 
enough, at least to explain the wide clinical variations in response to treatment. From this 
view point, it is true that serious contributions have been achieved, but more protocols must 
be conducted for a major understanding of MS pathology, as well as for a more effective 
response to treatment. 
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